NISCH

Nischarin · Q9Y2I1 · NISCH on Sugi Atlas →

28,241 patent compounds predicted against NISCH, 14,528 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL533283	0.67	15/20
SCHEMBL548286	0.55	13/20
SCHEMBL105024	1.00	12/20
Cirazoline (SCHEMBL126496)	1.00	12/20
Fenoxazoline (SCHEMBL193061)	1.00	12/20
SCHEMBL546875	1.00	12/20
Fenoxazoline (SCHEMBL317133)	0.97	12/20
Cirazoline (SCHEMBL466850)	0.97	12/20
SCHEMBL523059	0.66	12/20
Fenmetozole (SCHEMBL635495)	0.65	12/20
Fenmetozole (SCHEMBL635494)	0.63	12/20
SCHEMBL80782	0.62	12/20
Bromide (SCHEMBL82800)	0.61	12/20
SCHEMBL548346	0.54	12/20
SCHEMBL562867	0.53	12/20
SCHEMBL546268	0.78	11/20
Pyromellitic Acid (SCHEMBL216326)	0.71	11/20
Tymazoline (SCHEMBL250491)	0.70	11/20
SCHEMBL548343	0.50	11/20
SCHEMBL549207	0.55	10/20

Clinical trials — most relevant to NISCH by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study	PHASE4	COMPLETED
Non-inferiority, Open-label, Multicenter and Randomized Clinical Trial About the Treatment of Mild to Moderate Persistent Allergic Rhinitis	PHASE3	COMPLETED
Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome	PHASE3	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps	PHASE3	RECRUITING
Efficacy and Safety Study of Nidadd in the Management of Hyperlipidemia	PHASE3	COMPLETED
A Prospective Clinical Trial to Evaluate the Efficacy and Safety of Neurotropic B-Vitamins in Clinically Diagnosed Peripheral Sensory Polyneuropathy of Different Etiologies.	PHASE3	COMPLETED
Nitisinone for Type 1B Oculocutaneous Albinism	PHASE1/PHASE2	COMPLETED
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).	PHASE2	COMPLETED
Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma	PHASE2	COMPLETED
Effect of the Administration of L-arginine vs. Placebo in Patients Diagnosed With Presbyvestibulopathy.	PHASE2	WITHDRAWN
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps	PHASE2	COMPLETED
Study for the Prevention of Oral Mucositis (SPOM)	PHASE1/PHASE2	UNKNOWN
Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects	PHASE1	COMPLETED
Oral Nitrite and Nitrate in Healthy Normal Volunteer Adults	PHASE1	COMPLETED
Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation	PHASE1	WITHDRAWN
NI-0801 in Allergic Contact Dermatitis	PHASE1	COMPLETED
Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects	PHASE1	UNKNOWN
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants	PHASE1	RECRUITING
A Study of SENS 401 in Healthy Subjects	PHASE1	COMPLETED
Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria	nan	RECRUITING
A Study to Assess Safety and Improvement in Skin Barrier After Using 2 Facial Sunscreens in Adults With Sensitive Skin	nan	COMPLETED
Observational Prospective Study on Patients Treated With Norditropin®	nan	COMPLETED
Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)	nan	COMPLETED
Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis	nan	COMPLETED
An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)	nan	NO_LONGER_AVAILABLE
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)	nan	COMPLETED
Human Adaptation to High Altitude	nan	UNKNOWN
A Safety and Efficacy Study of Hymecromone Tablets for the Treatment of Patients With COVID-19.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NISCH binder may also engage these)

Protein	Name	Similarity
Q80TM9	—	1.000	Q80TM9 →
Q4G017	—	1.000	Q4G017 →
Q9UPV7	—	0.994	Q9UPV7 →
Q9BQI7	—	0.991	Q9BQI7 →
A2A3K4	—	0.991	A2A3K4 →
Q2NKQ1	—	0.991	Q2NKQ1 →
Q9NYI0	—	0.991	Q9NYI0 →
Q5TKR9	—	0.990	Q5TKR9 →
Q17QK1	—	0.990	Q17QK1 →
Q6P1I6	—	0.990	Q6P1I6 →
Q9BVR0	—	0.990	Q9BVR0 →
A7E379	—	0.990	A7E379 →
Q9Z2U2	—	0.990	Q9Z2U2 →
O95343	—	0.990	O95343 →
Q60610	—	0.990	Q60610 →
A3KMV1	—	0.990	A3KMV1 →
USP19	Ubiquitin carboxyl-terminal hydrolase 19	0.990	landscape →
P0C6P5	—	0.990	P0C6P5 →
A0JMQ9	—	0.990	A0JMQ9 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.989	landscape →
Q5R4R7	—	0.989	Q5R4R7 →
O43310	—	0.989	O43310 →
P59438	—	0.989	P59438 →
Q8TDY4	—	0.989	Q8TDY4 →
P51112	—	0.989	P51112 →
Q6NV72	—	0.989	Q6NV72 →
Q80TT8	—	0.989	Q80TT8 →
Q92539	—	0.989	Q92539 →
Q9VPH0	—	0.989	Q9VPH0 →
E9Q555	—	0.989	E9Q555 →